Company intelligence / Profile preview
AION Healthspan
Florida, United States
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
AION Healthspan has initiated a first-in-human Phase I/II clinical trial for its REJUVXL mesenchymal stem cell therapy targeting diabetic nephropathy and other forms of chronic kidney disease. The company also has discovery-stage programs focused on neoplasms via TNFR2 modulation. No published results from the ongoing trials yet.
- Therapeutic areas
- OncologyPulmonologyNephrology
- Modalities
- Mesenchymal stem cell therapycell therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on AION Healthspan.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AION Healthspan.